| | |
|---|---| [^1]
| **Protein Name** | ABCD2 Protein | [^2]
| **Gene** | [ABCD2](/genes/abcd2) | [^3]
| **UniProt ID** | [O14678](https://www.uniprot.org/uniprot/O14678) |
| **Family** | ABC transporter subfamily D ( peroxisomal) |
| **Tissue Expression** | Brain, liver, kidney, adrenal gland |
ABCD2 (ATP-Binding Cassette Subfamily D Member 2) is a peroxisomal membrane protein that belongs to the ATP-binding cassette (ABC) transporter family. Like its closely related paralog ABCD1 (which causes X-linked adrenoleukodystrophy when mutated), ABCD2 functions as a peroxisomal importer of very long-chain fatty acids (VLCFAs) and their CoA esters. While ABCD1 is the primary peroxisomal VLCFA transporter in the brain, ABCD2 can partially compensate and has distinct expression patterns and substrate specificities.
¶ Structure and Mechanism
ABCD2 is an integral peroxisomal membrane protein consisting of approximately 655 amino acids. Like other ABC transporters, it contains:
- Two transmembrane domains (TMDs): Six transmembrane helices that form the substrate translocation pore
- Two nucleotide-binding domains (NBDs): These bind and hydrolyze ATP to provide energy for transport
The protein forms homodimers or heterodimers (with ABCD1 or ABCD3) to create functional transporters. ABCD2 has preference for transporting C22-C26 very long-chain fatty acids, branched-chain fatty acids, and certain prostaglandins into the peroxisome for β-oxidation.
ABCD2 is expressed in multiple tissues with particularly high expression in:
- Brain: Neurons, astrocytes, and oligodendrocytes
- Liver: Hepatocytes
- Kidney: Renal tubules
- Adrenal gland: Cortical cells
- Testis: Spermatogenic cells
Within the brain, ABCD2 expression is notable in:
- Cerebral cortex neurons
- Hippocampal pyramidal neurons
- Cerebellar Purkinje cells
- White matter oligodendrocytes
ABCD2 plays a critical role in peroxisomal fatty acid metabolism:
- Imports VLCFAs (C22-C26) into peroxisomes
- Enables β-oxidation of very long-chain fatty acids
- Facilitates degradation of branched-chain fatty acids (e.g., phytanic acid)
- Participates in synthesis of bile acid intermediates
ABCD1 and ABCD2 can form functional heterodimers. This has therapeutic implications:
- Overexpression of ABCD2 can partially compensate for ABCD1 deficiency
- ABCD2 has distinct substrate preferences (longer chain lengths)
- Tissue-specific expression patterns differ between the two
While mutations in ABCD1 cause X-linked adrenoleukodystrophy (X-ALD), ABCD2 may modify disease severity:
- ABCD2 polymorphisms may influence age of onset
- ABCD2 expression can compensate for ABCD1 deficiency
- Therapeutic strategies targeting ABCD2 are being explored
Peroxisomal abnormalities are increasingly recognized in multiple neurodegenerative disorders:
Alzheimer's Disease (AD)
- Peroxisomal number and function are reduced in AD brain
- VLCFA metabolism is altered in AD
- ABCD2 expression changes in AD brain tissue
- Peroxisomal dysfunction contributes to oxidative stress
Parkinson's Disease (PD)
- Peroxisomal function is impaired in PD models
- ABCD2 may play a protective role in dopaminergic neurons
- Lipid metabolism alterations affect alpha-synuclein aggregation
Amyotrophic Lateral Sclerosis (ALS)
- Peroxisomal abnormalities observed in ALS models
- VLCFA metabolism dysregulated in ALS
- Energy metabolism defects involve peroxisomal pathways
ABCD2 may provide neuroprotection through:
- VLCFA homeostasis: Preventing VLCFA accumulation which is toxic to neurons
- Redox balance: Reducing oxidative stress through proper peroxisomal function
- Inflammation modulation: Peroxisomes produce anti-inflammatory mediators
- Mitochondrial support: Peroxisomal β-oxidation provides metabolic intermediates
Strategies targeting ABCD2 include:
- Gene therapy: Express ABCD2 in ABCD1-deficient cells
- Small molecule inducers: Drugs that upregulate ABCD2 expression
- Protein stabilization: Compounds that enhance ABCD2 function
- Functional complementation: Heterodimer formation with ABCD1
Several approaches are being investigated:
- Fibrates (PPAR agonists) can upregulate ABCD2 expression
- HDAC inhibitors modify ABCD2 transcription
- Gene editing approaches target ABCD2